Alpbio provides a hybrid platform that predicts, validates, and mitigates anti‑drug antibody (ADA) risk in therapeutic antibodies during lead optimization.
Funding
Funding not disclosed
Founders
Product
Problem
Anti‑drug antibody (ADA) responses frequently emerge late in biologics development, causing loss of efficacy, safety concerns, and costly program delays or terminations. The lack of early, predictive immunogenicity data forces developers to discover these risks only during clinical trials.
Solution
Alp Bio offers a hybrid platform that combines human tonsil organoid assays with generative AI to predict, validate, and mitigate immunogenicity risk during antibody lead optimization. The in‑silico screening layer evaluates candidate sequences against population‑scale immune response patterns to flag potential ADA‑forming epitopes. Flagged candidates are then tested in a proprietary ex‑vivo tonsil organoid system that reproduces human B‑cell and T‑cell interactions, providing experimental risk scores across diverse patient populations. Identified liabilities are re‑engineered using AI‑driven generative design, preserving therapeutic function while reducing immunogenic potential. The iterative lab‑in‑the‑loop workflow enables developers to de‑risk programs before entering Phase II, improving candidate selection and reducing downstream development costs.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing therapeutic antibodies who need early immunogenicity intelligence to guide candidate selection and optimization.
Features
- In‑silico ADA risk assessment using machine‑learning models trained on large‑scale immune response datasets
- Human tonsil organoid assay that captures key B‑cell/T‑cell interactions for ex‑vivo validation of immunogenicity
- Generative AI redesign of flagged epitopes to maintain activity while lowering ADA probability
- Integrated workflow that cycles between computational prediction, organoid testing, and AI‑guided redesign
- Scalable platform supporting lead candidate screening, risk stratification, and sequence optimization